CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer

Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer

Robert Vonderheide, MD, reports how a new type of immunotherapy is changing how physicians treat blood cancers in pediatric and young adult patients
  • Sponsored by

  • Overview

    For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer.

    But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer.  In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well.

    Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio



You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.